Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 28 peer-reviewed journal articles Updated
Medical Oncology

Treatment for Advanced and Metastatic Lung Cancer

At a Glance

For advanced or metastatic lung cancer, treatment is guided by biomarker and PD-L1 results, cancer type, symptoms, and overall health. Actionable mutations usually call for targeted therapy; cancers without them may need immunotherapy, chemotherapy, or both, with supportive care throughout.

In Stage IV (metastatic) lung cancer, the goal of treatment is to control the cancer throughout the body, manage symptoms, and maintain your quality of life for as long as possible [1]. Because modern medicine treats lung cancer based on its unique “fingerprints,” your first treatment step depends strongly on your biomarker and PD-L1 results, as well as your histology, symptoms, and overall health [2][3].

The “Driver” Pathway: Targeted Therapy First

If your testing identifies an actionable driver mutation (a specific genetic error that fuels the cancer’s growth), the standard first-line treatment is usually a targeted therapy [4]. These are typically daily pills that are more effective and often better tolerated than chemotherapy for these specific cancer types [5][6].

  • Why wait for results? When medically safe, it is highly recommended to wait for these results whenever possible. This is because immunotherapy generally does not work as well for many “driver-positive” cancers and can even increase the risk of side effects if given before certain targeted drugs [7][8]. However, if symptoms are severe, your team may need to begin treatment sooner.
  • Key Drivers: Your doctor will look for mutations like EGFR, ALK, ROS1, MET, RET, BRAF, and NTRK [4][9]. Each of these has dedicated medications that act as a “key” to turn off the cancer’s growth signal [6].

The “Driver-Negative” Pathway: Immunotherapy and Chemo

If no actionable driver mutation is found, your treatment is guided by your PD-L1 score, which tells doctors how likely your cancer is to respond to immunotherapy [10][11].

  • High PD-L1 (TPS ≥50%): You may be a candidate for immunotherapy alone (such as pembrolizumab). This can provide long-term control while avoiding the side effects of chemotherapy [12][13]. However, if your symptoms require rapid tumor shrinkage, chemoimmunotherapy may still be used.
  • Low or No PD-L1 (TPS <50%): The standard approach is usually a combination of chemotherapy and immunotherapy [14][15]. The chemotherapy works to shrink the tumor quickly, while the immunotherapy helps your immune system recognize the cancer over the long term [16].
  • Maintenance: After 4 to 6 cycles of initial treatment, if the cancer is stable or shrinking, you may move to maintenance therapy—continuing the immunotherapy (and sometimes one chemotherapy drug) to delay the cancer from progressing [17][18].

Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

For SCLC that has spread beyond one lung, treatment typically starts with a “cocktail” of chemotherapy and immunotherapy [17].

  • Standard Regimen: This usually involves four cycles of platinum-based chemotherapy plus an immunotherapy drug (like atezolizumab or durvalumab) [19][20].
  • Next Steps: If the cancer responds well, you will continue maintenance immunotherapy [17]. Your team may also discuss consolidative thoracic radiation (radiation to the main tumor in the chest) or monitoring your brain with frequent MRIs to catch any spread early [21][22].

The Exception: “Oligometastatic” Disease

Some patients have oligometastatic lung cancer, meaning the cancer has spread to a few isolated spots [23][24].

In these cases, doctors may take a more aggressive approach. After initial systemic treatment (chemo or targeted therapy) has stabilized the disease, they may use “local therapies” like surgery or SBRT/SABR (high-dose pinpoint radiation) to treat each of those individual spots [23][25]. The goal is to maximize the time before the cancer starts growing again, and in carefully selected patients, this can improve disease control [26][27].

A Note on Clinical Trials and Supportive Care

For all stages of metastatic lung cancer, clinical trials are often considered a preferred option [24]. They can provide access to the very latest therapies, such as new targeted drugs or “bispecific” antibodies like tarlatamab, which is an approved option for patients whose SCLC progresses after platinum chemotherapy [28]. Additionally, palliative and supportive care should be integrated immediately to actively manage pain, breathlessness, and emotional distress alongside your cancer treatment.

Common questions in this guide

How do doctors choose the first treatment for metastatic lung cancer?
The choice depends on whether the tumor has an actionable driver mutation, its PD-L1 score and histology, your symptoms, and your overall health. A driver mutation usually leads to targeted therapy, while cancers without one may be treated with immunotherapy alone or with chemotherapy and immunotherapy.
Why might my oncologist wait for biomarker results before starting treatment?
Biomarker results can show whether a targeted drug is likely to work and whether immunotherapy is an appropriate first choice. When it is medically safe, waiting can help avoid starting a less suitable treatment, although severe symptoms may require treatment before all results are available.
What does a PD-L1 score mean for lung cancer treatment?
PD-L1 is a tumor test that helps estimate how likely the cancer is to respond to immunotherapy. For cancers without an actionable driver, a high score, often 50% or higher, may make immunotherapy alone an option for some patients, while a lower score often leads to chemotherapy plus immunotherapy; symptoms and other factors also matter.
How is extensive-stage small cell lung cancer usually treated?
Treatment commonly begins with four cycles of platinum-based chemotherapy combined with an immunotherapy drug such as atezolizumab or durvalumab. If the cancer responds or remains stable, maintenance immunotherapy may follow, and the team may discuss chest radiation or regular brain MRI monitoring.
Can a few metastatic spots be treated directly?
Some patients with oligometastatic lung cancer have only a few isolated areas of spread. After systemic treatment stabilizes the disease, doctors may use surgery or focused radiation such as SBRT or SABR to treat individual spots, particularly when an aggressive approach is appropriate.
What role do clinical trials play in metastatic lung cancer care?
Clinical trials may be considered for metastatic lung cancer and can provide access to newer treatments, including targeted drugs or other medicines being studied. Ask your oncology team which trials match your lung cancer type, biomarker results, previous treatments, and overall health.
Can palliative care start while I am receiving cancer treatment?
Yes. Palliative and supportive care can begin alongside cancer treatment to relieve pain, breathlessness, and emotional distress and to help maintain quality of life. This support can be provided throughout the illness and is not limited to the end of life.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my lung cancer driver-positive, and is a targeted therapy the right first step?
  2. 2.Given my PD-L1 score, histology, and symptoms, do you recommend immunotherapy alone or combined with chemotherapy?
  3. 3.For my extensive-stage SCLC, what is the plan for maintenance therapy after my initial chemoimmunotherapy cycles?
  4. 4.If I have only a few isolated spots of cancer, are we planning to use local therapies like radiation to treat those specific areas?
  5. 5.What clinical trials are available at this center or nearby for my specific situation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (28)
  1. 1

    The impact of cancer information overload on negative emotions in newly diagnosed lung cancer patients: the mediating role of fear of progression and the moderating role of social support.

    Xu F, Zhang J, Li Q, et al.

    Frontiers in psychiatry 2025; (16()):1676219 doi:10.3389/fpsyt.2025.1676219.

    PMID: 41234423
  2. 2

    Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.

    Osmani L, Askin F, Gabrielson E, Li QK

    Seminars in cancer biology 2018; (52(Pt 1)):103-109 doi:10.1016/j.semcancer.2017.11.019.

    PMID: 29183778
  3. 3

    Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

    Lindeman NI, Cagle PT, Aisner DL, et al.

    Archives of pathology & laboratory medicine 2018; (142(3)):321-346 doi:10.5858/arpa.2017-0388-CP.

    PMID: 29355391
  4. 4

    Dermatologic Adverse Event Mitigation and Management Strategies with Amivantamab + Lazertinib Therapy for Advanced Non-Small Cell Lung Cancer: A Vodcast.

    Nguyen D, Santos ES

    Targeted oncology 2025; (20(5)):737-742 doi:10.1007/s11523-025-01163-3.

    PMID: 40544186
  5. 5

    Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.

    Harrison PT, Vyse S, Huang PH

    Seminars in cancer biology 2020; (61()):167-179 doi:10.1016/j.semcancer.2019.09.015.

    PMID: 31562956
  6. 6

    What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?

    Ricciuti B, Awad MM

    Cancer journal (Sudbury, Mass.) 2020; (26(6)):485-495 doi:10.1097/PPO.0000000000000489.

    PMID: 33298719
  7. 7

    TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer.

    Okamoto I, Kuyama S, Girard N, et al.

    Future oncology (London, England) 2024; (20(37)):2927-2936 doi:10.1080/14796694.2024.2409621.

    PMID: 39469838
  8. 8

    Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors.

    Nakagawa N, Kawakami M

    Frontiers in oncology 2022; (12()):952393 doi:10.3389/fonc.2022.952393.

    PMID: 36033471
  9. 9

    Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia.

    Mahrous M, Omar Jebriel A, Allehebi A, et al.

    Cureus 2023; (15(7)):e41992 doi:10.7759/cureus.41992.

    PMID: 37492039
  10. 10

    Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record.

    Pagni F, Malapelle U, Doglioni C, et al.

    Cancers 2020; (12(7)) doi:10.3390/cancers12071800.

    PMID: 32635634
  11. 11

    Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer.

    Li T, Ma W, Al-Obeidi E

    Cancers 2024; (16(13)) doi:10.3390/cancers16132350.

    PMID: 39001412
  12. 12

    First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.

    Satouchi M, Nosaki K, Takahashi T, et al.

    Cancer science 2020; (111(12)):4480-4489 doi:10.1111/cas.14647.

    PMID: 32926507
  13. 13

    Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.

    Saxena P, Singh PK, Malik PS, Singh N

    Current treatment options in oncology 2020; (21(8)):69 doi:10.1007/s11864-020-00768-2.

    PMID: 32720019
  14. 14

    Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis.

    Huang S, Huang Z, Huang X, et al.

    Frontiers in immunology 2024; (15()):1375136 doi:10.3389/fimmu.2024.1375136.

    PMID: 39072325
  15. 15

    Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up.

    Gadgeel SM, Rodríguez-Abreu D, Halmos B, et al.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2024; (19(8)):1228-1241 doi:10.1016/j.jtho.2024.04.011.

    PMID: 38642841
  16. 16

    Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.

    Guaitoli G, Tiseo M, Di Maio M, et al.

    Translational lung cancer research 2021; (10(6)):2890-2916 doi:10.21037/tlcr-20-941.

    PMID: 34295687
  17. 17

    First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

    Horn L, Mansfield AS, Szczęsna A, et al.

    The New England journal of medicine 2018; (379(23)):2220-2229 doi:10.1056/NEJMoa1809064.

    PMID: 30280641
  18. 18

    Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis.

    Zhang B, Zhong R, Shi C, et al.

    Nature communications 2026; (17(1)).

    PMID: 42185290
  19. 19

    Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

    Paz-Ares L, Dvorkin M, Chen Y, et al.

    Lancet (London, England) 2019; (394(10212)):1929-1939 doi:10.1016/S0140-6736(19)32222-6.

    PMID: 31590988
  20. 20

    FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.

    Mathieu L, Shah S, Pai-Scherf L, et al.

    The oncologist 2021; (26(5)):433-438 doi:10.1002/onco.13752.

    PMID: 33687763
  21. 21

    Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations.

    Sun A, Abdulkarim B, Blais N, et al.

    Lung cancer (Amsterdam, Netherlands) 2023; (179()):107166 doi:10.1016/j.lungcan.2023.03.002.

    PMID: 36944282
  22. 22

    Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis.

    Palma DA, Warner A, Louie AV, et al.

    Clinical lung cancer 2016; (17(4)):239-44.

    PMID: 26498503
  23. 23

    Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.

    Iyengar P, All S, Berry MF, et al.

    Practical radiation oncology 2023; (13(5)):393-412 doi:10.1016/j.prro.2023.04.004.

    PMID: 37294262
  24. 24

    American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer.

    Amini A, Verma V, Simone CB, et al.

    International journal of radiation oncology, biology, physics 2022; (112(2)):361-375 doi:10.1016/j.ijrobp.2021.09.022.

    PMID: 34571054
  25. 25

    Changing equipoise in the landscape of radiation for oligometastatic lung cancer.

    Schroeder SR, Leenders M, Iyengar P, de Ruysscher D

    Translational lung cancer research 2019; (8(Suppl 2)):S184-S191 doi:10.21037/tlcr.2019.07.09.

    PMID: 31673523
  26. 26

    Evaluation of local aggressive lung therapy versus systemic therapy in oligometastatic non-small cell lung cancer: a systematic review and meta-analysis.

    Zhang C, Ma N, Zhang Q, et al.

    Journal of thoracic disease 2021; (13(10)):5899-5910 doi:10.21037/jtd-21-957.

    PMID: 34795938
  27. 27

    Current Controversies and Challenges in Non-Oncogene-Addicted Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Review.

    Jongbloed M, Bortolot M, Willmann J, et al.

    JAMA oncology 2025; (11(11)):1385-1392 doi:10.1001/jamaoncol.2025.2891.

    PMID: 40906489
  28. 28

    Small Cell Lung Cancer: A Review.

    Kim SY, Park HS, Chiang AC

    JAMA 2025; (333(21)):1906-1917 doi:10.1001/jama.2025.0560.

    PMID: 40163214

This page explains treatment options for advanced and metastatic lung cancer for educational purposes only and does not replace advice from your oncology team. Your treatment plan should reflect your cancer type, biomarker results, symptoms, and overall health.

Get notified when new evidence is published on lung cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.